Alethio Therapeutics announced an oversubscribed USD 90 million Series A to advance treatments for myeloproliferative neoplasms. Sofinnova Partners and RA Capital co led the round alongside founding investor Oxford Science Enterprises, with Cancer Research Horizons and the University of Oxford also participating. The Oxford biotechnology company is developing ATX 011, a therapy intended to reduce disease driving cells in essential thrombocythaemia. Chief executive Rohit Batta plans to use the financing for Phase 1 and Phase 2a studies and additional programmes. The candidate remains preclinical, so its proposed mechanism and therapeutic potential are not evidence of safety or efficacy in patients.
Alethio raises USD 90m for blood cancer therapies
Sofinnova, RA Capital and Oxford Science Enterprises co lead the Series A

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


